drugset / Trial / NCT03300427
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase IV, prospective, randomized, double-blind, double-dummy, parallel-group study. The study assessed the effects of 6 weeks of stable sacubitril/valsartan therapy, as compared with valsartan therapy, on the efficiency of cardiac work in patients with NYHA II-III heart failure (HF) and reduced systolic function using 11C-acetate positron emission tomography (PET) and echocardiography.
Timeline
- Start
- 2018-07-05
- Primary completion
- 2022-03-23
- Completion
- 2022-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacubitril | Small molecule | 100 mg | Oral |
| Subject | Sacubitril | Small molecule | 200 mg | Oral |
| Comparator | Valsartan | Small molecule | 80 mg | Oral |
| Comparator | Valsartan | Small molecule | 160 mg | Oral |